Back to top
more

ImmunoGen, Inc. (IMGN)

(Delayed Data from NSDQ)

$2.88 USD

2.88
5,883,771

+0.38 (15.20%)

Updated May 3, 2019 04:00 PM ET

After-Market: $2.93 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Analysts Estimate ImmunoGen (IMGN) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

ImmunoGen (IMGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Ionis Pharmaceuticals (IONS) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of 65.09% and 3.82%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Cigna (CI) to Post Q4 Earnings: Here's What You Should Know

by Zacks Equity Research

Cigna's (CI) fourth-quarter results are likely to reflect increased Evernorth and Cigna Healthcare profits.

Can Humana's (HUM) Q4 Earnings Beat on Healthcare Services?

by Zacks Equity Research

Humana's (HUM) fourth-quarter results are likely to reflect surging Healthcare Services profits on strong pharmacy business.

HCA Healthcare (HCA) to Post Q4 Earnings: What's in the Cards?

by Zacks Equity Research

HCA Healthcare's (HCA) fourth-quarter results are likely to reflect increased equivalent admissions and outpatient surgery cases.

Elevance Health (ELV) to Post Q4 Earnings: What to Expect

by Zacks Equity Research

Elevance Health's (ELV) fourth-quarter results are likely to reflect higher premiums, Commercial & Specialty Business' sales and total expenses.

Aurinia (AUPH) Soars 37.5%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Aurinia (AUPH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Company News for Dec 30, 2022

by Zacks Equity Research

Companies in The News Are: IMGN, TGTX, TSLA, MSFT

Gilead (GILD) To Get Full Rights for Jounce's Immunotherapy

by Zacks Equity Research

Gilead Sciences (GILD) is set to buy the remaining rights to the potential first-in-class immunotherapy GS-181 from Jounce Therapeutics.

Gilead (GILD) Partners With Arcellx, ImmunoGen in Oncology

by Zacks Equity Research

Gilead (GILD) announces deals with Arcellx, Inc. and ImmunoGen to strengthen its oncology pipeline.

ImmunoGen (IMGN) Gets Accelerated FDA Approval for Ovarian Cancer Drug

by Zacks Equity Research

ImmunoGen (IMGN) receives accelerated FDA approval for its lead drug mirvetuximab soravtansine-gynx, to be marketed as Elahere. The drug will treat adults with ovarian cancer.

ImmunoGen (IMGN) Q3 Loss Wider, Sales Beat, '22 View Up

by Zacks Equity Research

ImmunoGen (IMGN) reports a wider-than-expected loss in third-quarter 2022. Nevertheless, it beat revenue estimates. The company raises its financial guidance for 2022

ImmunoGen (IMGN) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

ImmunoGen (IMGN) delivered earnings and revenue surprises of -19.23% and 30.16%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Should You Buy ImmunoGen (IMGN) Ahead of Earnings?

by Zacks Equity Research

ImmunoGen (IMGN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Aquestive Therapeutics (AQST) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of 23.33% and 7.30%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Cassava Sciences (SAVA) to Report Q3 Earnings: What's in Store?

by Zacks Equity Research

Cassava Sciences (SAVA) is expected to provide an update on its pipeline candidates during its third-quarter earnings.

Marinus Pharmaceuticals (MRNS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Marinus Pharmaceuticals (MRNS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zoetis (ZTS) to Report Q3 Earnings: Is a Beat in Store?

by Zacks Equity Research

Zoetis (ZTS) is anticipated to report positive earnings and revenues for third-quarter 2022. It will also provide an update on its pipeline on the earnings call.

ImmunoGen (IMGN) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

ImmunoGen (IMGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Agenus (AGEN) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

On Agenus' (AGEN) third-quarter earnings call, investor focus is likely to be on the company's progress with the developments of its pipeline candidates.

Novavax (NVAX) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

On Novavax's (NVAX) third-quarter earnings call, investors' focus is likely to be on the sales figures of its COVID-19 vaccine.

Why Is Pacira (PCRX) Down 9.2% Since Last Earnings Report?

by Zacks Equity Research

Pacira (PCRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Immunogen (IMGN) Provides Preliminary Data on Rare Blood Cancer Candidate

by Zacks Equity Research

Immunogen (IMGN) announces preliminary data on its CADENZA study evaluating pivekimab in blastic plasmacytoid dendritic cell neoplasm.

Esperion Therapeutics (ESPR) Up 29.3% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

ImmunoGen (IMGN) Q2 Earnings and Revenues Miss Estimates

by Zacks Equity Research

ImmunoGen (IMGN) reports a wider-than-expected loss for second-quarter 2022. It also misses revenue estimates.